Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics develops drug candidates for obesity, fatty liver disease and a rare inherited brain and nerve disorder. It last closed at $26.88 on Nov 17, up 0.30% on the day. VKTX reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 3 analysts is $99.00 (+268.3% from the last close), with a high of $118.00 and a low of $85.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in VKTX, 0% of them bullish and 100% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From VKTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on VKTX in the past 90 days. The average target is $99.00, with a high of $118.00 and a low of $85.00, compared with the last close of $26.88.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 31 | Canaccord Genuity | Target raised | Buy | $106 → $118 |
| Oct 20 | Canaccord Genuity | Target lowered | Buy | $114 → $106 |
| Oct 15 | UBS | Initiated | Buy | $94 |
| Oct 7 | Truist Securities | Target lowered | Buy | $87 → $85 |
| Sep 23 | Truist Securities | Maintained | Buy | $87 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 20% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the 20 day average at $26.77, and the nearest resistance the Pivot at $27.28.
| RSI (14) | 47.21 | Middle of its range | Neutral |
| MACD | -0.20 | Above its signal line | Bullish |
| Stochastic | 57.3 | Middle of its range | Neutral |
| ADX (14) | 14.4 | No clear trend | |
| Williams %R | -56.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 30.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +3.0% | Change over 10 sessions | Bullish |
| ATR (14) | $1.90 | Typical daily range, 7.1% of price |
| RSI (14) | 44.04 | Middle of its range | Neutral |
| MACD | -1.67 | Below its signal line | Bearish |
| Stochastic | 19.9 | Near the bottom of its range | Oversold |
| ADX (14) | 10.9 | No clear trend | |
| Williams %R | -84.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -85.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −15.9% | Change over 10 sessions | Bearish |
| ATR (14) | $4.14 | Typical daily range, 15.4% of price |
What happened before
See how VKTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How VKTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in VKTX in the last 90 days.
VKTX Institutional Ownership
Full report →- ▲243 buying vs 191 selling
- ▲Held by funds +14.8 pts
- ▲Funds holding +8
- ▼Superinvestors: 1 added, 3 cut
- ▼Put/call 0.16 to 0.48
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 444 | 436 | +1.8% |
| In funds' top 10 | 8 | 5 | +60.0% |
| Held by funds | 74.4% | 59.6% | +14.8 pts |
| New / increased | 82 / 161 | 69 / 146 | +13.0% |
| Reduced / sold out | 125 / 66 | 128 / 53 | +5.5% |
| Put/call ratio | 0.48 | 0.16 | +190.3% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VKTX is in one of them and how their past VKTX trades turned out.
VKTX News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered VKTX in an article yet. Here's the latest on the wider market.
About Viking Therapeutics
Viking Therapeutics is a biopharmaceutical company based in San Diego, California, that develops drug candidates for metabolic and endocrine conditions. Its lead program, VK2735, is being studied as both an injectable and an oral tablet for obesity. The company is also developing VK2809 for fatty liver disease, known as NASH or MASH, and VK0214 for adrenoleukodystrophy, a rare inherited disorder that affects the brain and nerves. Its programs are in clinical development.
- Headquarters
- San Diego, CA



